Telitacicept versus mycophenolate mofetil in IgA nephropathy: a real-world comparative study of efficacy, renal outcomes and safety
Telitacicept may offer better efficacy compared with MMF for proteinuria reduction in high-risk IgAN patients, while reducing combined glucocorticoid requirements and demonstrating a more favourable safety profile. These advantages position it as a promising therapeutic option, warranting further randomized validation.
Authors
- Xirong Wu (ORCID: https://orcid.org/0000-0002-3793-5462)
- Guisen Li (ORCID: https://orcid.org/0000-0003-1970-9979)
- Wei Qin (ORCID: https://orcid.org/0000-0003-4246-5431)
- Min Yu (ORCID: https://orcid.org/0000-0002-3942-261X)
- Kun Peng (ORCID: https://orcid.org/0009-0003-9661-1868)
- Xiang Zhong (ORCID: https://orcid.org/0000-0003-3585-4201)
- Xisheng Xie (ORCID: https://orcid.org/0000-0002-2268-7662)
- Li Wang (ORCID: https://orcid.org/0000-0002-0910-0361)
- Wei Wang (ORCID: https://orcid.org/0000-0001-5664-7725)
- Yongjun He (ORCID: https://orcid.org/0000-0002-2697-5012)
- Kaixiang Liu (ORCID: https://orcid.org/0000-0002-8053-4701)
- Shasha Chen
Institutions
- North Sichuan Medical University (CN)
- University of Electronic Science and Technology of China (CN)
- Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
Publication Details
- Journal
- Clinical Kidney Journal
- Published
- 2025-08-12
- DOI
- https://doi.org/10.1093/ckj/sfaf261
- Citations
- 5
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 7.15
Funders
- National Natural Science Foundation of China
- Department of Science and Technology of Sichuan Province